Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2017 Mar 28;19(1):42.
doi: 10.1186/s13058-017-0830-9.

Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Yi Fang Lee  1 , Lance David Miller  2 , Xiu Bin Chan  1 , Michael A Black  3 , Brendan Pang  4 , Chee Wee Ong  4 , Manuel Salto-Tellez  5   6 , Edison T Liu  7 , Kartiki V Desai  8
Affiliations
Published Erratum

Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Yi Fang Lee et al. Breast Cancer Res. .
No abstract available

PubMed Disclaimer

Figures

Fig. 8
Fig. 8
JMJD6 expression affects SMAD phosphorylation. Immunoblots show that the level of total SMAD2/3, phosphorylated SMAD2 and phosphorylated SMAD3 are decreased in MCF-7 J1-OE clones, and increased in JMJD6 siRNA-mediated knock-down in MCF-7 and MDA-MB231. The numbers next to the SMAD2P/3P denote the expected sites of phosphorylation detected by the antibodies. N.S. denotes non-specific bands from the blots which indicate equal loading of the protein lysates
See this image and copyright information in PMC

Erratum for

References

    1. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast cancer research: BCR. 2012;14(3):R85. doi: 10.1186/bcr3200. - DOI - PMC - PubMed

Publication types

LinkOut - more resources